Cost and Funding
Payment Suspension Plans

Competitive Pricing Quotes

The identified providers of Stabilization and Suspension

For most of cryonics history (which began in the mid-1960s), all of the cryonics organizations offering cryonics services have been in the United States. In 2005 a cryonics organization was created in Russia (just northwest of Moscow) and there are plans for another cryonics organization in Australia to offer perfusion and storage of cryonics patients within a few years.

Alcor Life Extension Foundation, Scottsdale, Arizona

American Cryonics Society, Cupertino, California

Cryonics Institute, Clinton Township, Michigan

EUCrio, Braga, Portugal

KrioRus, Alabychevo, Russia

Suspended Animation, Inc Boynton Beach, Florida

Trans Time, Inc., San Leandro, California

Cryonics Asia, Ltd., Koh Samui,Thailand, Israel and Hong Kong

Alcor Life Extension Foundation and the American Cryonics Society (ACS) are organized as 501(c)3 charitable organizations, whereas the Cryonics Institute (CI) is simply a non-profit corporation. Although Suspended Animation, Inc. (SA) is ostensibly a for-profit company, it is mainly engaged in research and development of cryonics capabilities financed by the principals of the Life Extension Foundation. By 2012 KrioRus had relocated to a facility closer to Moscow.

Cryonics Asia, Ltd., is structured principally as a for profit company looking at developing complete facilities on the island on Kho Samui, Thailand.

The Cryonics Association of Australasia (CAA) is a non-profit organization registered in Victoria providing membership suspension arrangements.

Stasis Systems Australia (SSA) is a non-profit organization formed to build and operate Australia's first cryonic storage facility.

Cryonics Services Currently Offered

Standby/Stabilization/Transport (SST) involves standing by the bedside of a medically terminal patient destined to be cryopreserved, the application of a heart-lung resuscitator and ice-water cooling as soon as possible after declaration of death, and transport to a perfusion facility while tissues are still being stabilized at low temperature

Cryopreservation involves Perfusion and Storage. Perfusion is the replacement of normal body fluid with cryoprotective solutions to reduce or prevent ice formation at cryogenic temperatures while the patient is the storage of a cryonics patient in liquid nitrogen.

Not all cryonics services are offered by all cryonics organizations. Patient administration service is offered by cryonics organizations that sign-up Members who are to be cryopreserved upon legal death and maintain responsibility for those Members while they are Patient's in cryopreservation storage. These maybe categorized as Value Added Resellers (VARs).

These are the services that need to be provided to accomplish successful Cryopreservation and the chance for a future outcome that takes full advantage of the Medical Advances Timeline that, hopefully, will make for a viable resuscitation.

The Cryonics reach, into the Asian market, is has been quite shallow as of this writing. It may come in the future with Cryopreservation and Storage facilities implemented in Australia and China. Right now, for a Cryonics patient in Asia needing Standby/Stabilization/Transport (SST), these services are not in place.

Cryonics Asia, Ltd seeks to change all of that in the very near future with proposals in place to operate full vitification, preservation and suspension and storage facilities in Thailand serving all of South East Asia with the addition of hospice and terminally ill stand-by services.

Location facilities to be establish, in conjunction with an existing hospital for terminal care, on Koh Samui Island, Thailand.

The Transport element and time to Perfusion is particularly difficult in transferring the patient from Asia while maintaining stabilization for a much longer period of time. Now, the stabilized patient, coming from Asia, must seek out the nearest Cryopreservation facilities located in the USA.

This Asian market is more than ripe to be serviced by a viable regional organization.

There is a Cost

The following Average Estimates come from current recognized providers:

Minimum Cryopreservation Funding:

  • $200,000.00 Whole Body Cryopreservation ($110,000 placed in to a Patient Care Trust, $60,000 for cryopreservation, $30,000.00 to the CMS Fund).
  • $ 80,000.00 Neurocryopreservation ($25,000 placed into a Patient Care Trust, $30,000 for cryopreservation, $25,000.00 to the CMS Fund).

Surcharges:

  • $ 15,000.00 Surcharge for cases in the United Kingdom.
  • $ 25,000.00 Surcharge for cases outside the U.S., Canada, and the United Kingdom.
  • $ 25,000.00 Surcharge for cryopreservation of non-members arranged by an approved third party such as a value added reseller (VAR)
  • $ 50,000.00 Surcharge for cryopreservation of non-members arranged by an approved third party such as a value added reseller (VAR)
  • We would expect these Surcharges to be added to the cost of the Member residing in Asia

Membership Dues: Most service purveyors require Membership Dues from all living Members to support the advancement of its programs. Membership is required in order to become accepted as a fully paid Member.

Current Membership Dues average around:

  • $620.00 annually or $312 semi-annually or $156.00 quarterly or $53 monthly

Standby Charges

All Members residing, in the continental U.S. and Canada, will receive Comprehensive Member Standby (CMS) services which include all rescue activities up through the time the legally pronounced Member is delivered as a patient to the Cryopreservation and Storage facility operating room.

Current CMS charges are around

$15.00 monthly, $45.00 quarterly, $90 semi-annually, or $180.00 annually

*All of these cost estimates are from the high end of the competitive range

The preferred Funding Mechanism is a Commercial Insurance Policy payable to the Cryonics Service Organization (Cryonics Asia, Ltd.) guaranteeing fulfillment by both parties to the Cryopreservation Agreement

NOTE:

It is the strong opinion of Cryonics Asia. Ltd. that “posted” cryonics pricing and cost estimates emanating primarily from the USA non-profit providers (possibly with the exception of ALCOR) are far out of line with what one would actually be facing on a case-by-case ALL IN quotation bases. It is not just the cheapest cost to get the body into a nitro deep freeze tank.

Any low-end estimates should be viewed as out-and-out fraud where the patient will find themselves greatly underfunded in suspension maintenance and resuscitation cost contingencies at future dates.


Cryonics Asia, Ltd. estimates the patient’s expected ALL IN costs to be in the eventual range of $350,000 to $450,000 USD.

This will assure a “gold standard” preservation and suspension as well as adequate funding to assure resuscitation. Interest rates and inflation assumptions will largely affect trust capital preservation over a 200 year horizon. Reliance on foundation donations and an eventual trans-humanist world of “singularity” is fantasy thinking or poor probabilities at best.

Cheap preservation and suspension quotations are not the entire story.

Each member’s situation must be evaluated on a case-by-case basis. Cryonics Asia, Ltd. is ready to consult with you and your financial advisor on these critical financial matters.

Our Due Diligence and Disclosure Responsibilities

If, as a company, Cryonics Asia, Ltd. are selling the Cryonics Preservation Solution as a reasonably viable financial pursuit for clients (potential patents) or investors (potential stock holders) or members (foundation donors), then due diligence requires certain consideration and realization on the part of individuals being ask to commit valuable resources to some future conclusion.

Disclosure is a paramount consideration in planning and executing our business model.

As a company, either for profit or non-profit membership foundation, our company will have to function under the rules of full disclosure as well as strong and verifiable Trusteeship of Funds held for solicited purposes. This would include the funding of patent cryonic preservation, insurance beneficiary payments under contract, lump sum full payment receipts, membership donations and funding of Scientific Research. Operations costs and financial sources and application of current and future funding would need to be audited and reported on a regular basis.

The single key element of disclosure, in all cases of solicitation for funding of company operations, including patent preservation performance costs, would be:

The Probability that Cryonics will work

This analysis has sometimes been compared with Pascal's Wager.

Estimating the odds

People often ask "What is the probability that cryonics will work?"

The short answer: discounting dystopian futures, assuming a good quality of cryopreservation, and assuming that molecular nanotechnology (or MNT) is developed more or less as expected, the overall probability of success seems quite high - likely exceeding 85%.

How we arrived at this answer? The simplest framework is to break down the probability of success into separate independent variables and then analyze each variable. This task is not as easy as it looks.

1. You must avoid Information-theoretic death.

The destruction of the information within a human brain to such an extent that recovery of the original person is theoretically impossible by any physical means

2. Technology to revive you must be developed and applied.

This framework is intended to provide clearly independent probabilities, so that multiplication of the probabilities can be used to draw conclusions about the overall probability of success.

Information Destruction, in the extreme, is that the patent’s memories, personality, hopes, dreams, etc. have been destroyed. Perhaps the most significant risk is caused by deterioration of the brain prior to legal death from neurodegenerative diseases We can reasonably expect that the technology required to revive a cryopreserved patient and restore them to health will also be able to reverse dementia, but The extent of such irreparable memory loss (as opposed to damage to retrieval mechanisms) is not known at this time. We cannot, at the present time, distinguish reliably between these two possibilities in most cases. What is "unacceptable memory loss? The answers are likely to vary widely from person to person.

Future Medical Technology will be no mere incremental or evolutionary advance over today's medicine. The coming ability to arrange and rearrange molecular and cellular structure in almost any way consistent with physical law will let us repair or replace almost any tissue in the human body. Whether it's a new liver, a more vital heart, a restored circulatory system, removing some cancerous cells, or some other treatment -- at some point, nanomedicine should let us revitalize the entire human body and even revive someone who was cryopreserved today. And, also the interesting discussion The Molecular Repair of the Brain:

Those interested in pursuing this subject should read:

Cryo-probability which discusses the chances of success

http://merkle.com/cryo/probability.html

The Molecular Repair of the Brain which discusses repair technologies that are clearly feasible in principle

http://www.merkle.com/cryo/techFeas.html